COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES COMPRISING A BCAT1 INHIBITOR
Application
US20260076937A1
Kind: A1
Mar 19, 2026
Assignee
Seoul National University R&DB Foundation
Inventors
Won-Woo Lee, Yeon Joon Kang
Abstract
Disclosed herein are branched chain amino acid transaminase 1 (BCAT1) inhibitors and uses thereof. More specifically, disclosed are BCAT1 inhibitors that limit amino acid metabolism essential for CD4+ T-cell responses and their use in preventing, improving, or treating inflammatory disease or autoimmune disease. By identifying that BCAT1 acts as a major regulator in the inflammatory response of CD4+ T-cells, it is possible to regulate the inflammatory response by CD4+ T cells secreting interleukin-17 (IL-17), which is a major immune cell of autoimmune diseases, by utilizing a BCAT1 inhibitor.
CPC Classifications
A61K 31/343
A61K 9/0053
A61K 31/19
A61K 31/20
A61P 29/00
Filing Date
2025-05-16
Application No.
19210387